Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $243.6M rose 55.4% year over year, behind the +58.9% change in trailing-twelve-month revenue. Sequentially, it rose 13.7% from the prior quarter. Over 3 fiscal years it compounded at +45.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $1.05B (+54.9%) for the fiscal year ending Dec 2026, a slowdown from the +60.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $243.6M+13.7% QoQ
- Last fiscal yearDec 2025
- $677.56M+60.1% YoY
- LTMJun 2026
- $840.85M+58.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +55.4% | +44.1% | -11.2 pp |
| 1 year | +60.1% | +54.9% | -5.2 pp |
| 3-year CAGR | +45.5% | +31.7% | -13.8 pp |
| 5-year CAGR | +23.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 677.56M USD
- Year-over-year change
- +60.1%
- 4-year CAGR
- +104.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 677.56M | +60.1% |
| FY2024 | 2024-12-31 | 423.24M | +56.6% |
| FY2023 | 2023-12-31 | 270.26M | +22.7% |
| FY2022 | 2022-12-31 | 220.18M | +471.2% |
| FY2021 | 2021-12-31 | 38.54M | — |
Revenue vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 revenue of $840.85M is the highest of the 10 companies compared; the peer median is $8.37M.
- Its year-over-year change of +58.9% is the 3rd highest of 7, against a peer median of -18.9%.
- Over three fiscal years its annual growth of +45.5% compares with a peer median of -4.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $840.85M | +58.9% | +45.5% | |
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Mar 2026 | $369.38M | +15.2% | +22.4% | |
| LTM Mar 2026 | $232.39M | +107.7% | +183.6% | |
| LTM Sep 2026 | $90.49M | — | — | |
| LTM Mar 2026 | $8.37M | -52.9% | -35.9% | |
| LTM Sep 2026 | $7.1M | — | — | |
| LTM Jun 2026 | $1.9M | -60.8% | -31.8% | |
| LTM Mar 2026 | $59K | -86.6% | -85.2% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $0 | — | — |
| Peer median (excluding KNSA) | $8.37M | -18.9% | -4.7% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Cost of Revenue | 9.1M | 22.9M | 56.52M | 60.91M | 307.41M |
| Gross Profit | 29.44M | 197.29M | 213.74M | 362.33M | 370.15M |
| Gross Margin | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| Research & Development | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M |
| Selling, General & Admin | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Operating Expenses | 186.08M | 187.51M | 238.93M | 407.95M | 292.93M |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| EBITDA | (154.18M) | 13.43M | (14.31M) | (34.46M) | 90.42M |
| EBITDA Margin | -400.0% | 6.1% | -5.3% | -8.1% | 13.3% |
| Operating Income | (156.64M) | 9.77M | (25.2M) | (45.62M) | 77.22M |
| Operating Margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Interest Income | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Income Before Tax | (156.54M) | 11.03M | (16.65M) | (36.15M) | 88.87M |
| Pre-Tax Margin | -406.1% | 5.0% | -6.2% | -8.5% | 13.1% |
| Income Tax Expense | 1.39M | (172.34M) | (30.74M) | 7.04M | 29.86M |
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | 59.01M |
| Net Margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (Basic) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 |
| EPS (Diluted) | (2.30) | 2.60 | 0.20 | (0.60) | 0.75 |
| Weighted Avg Shares | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M |
| Weighted Avg Shares (Diluted) | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.